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A B S T R A C T
Objective: The diagnostic efficacy of the BDProbeTEC ET Mycobacterium tuberculosis (MTB) 
complex direct detection assay (DTB) performed on bronchoalveolar lavage (BAL) specimens 
and sputum smears was compared with acid-fast bacilli (AfB) smear microscopy. 
Method: AfB smear microscopy, DTB and culture results of 286 patients with pulmonary 
tuberculosis were retrospectively reviewed. A total of 120 patients provided expectorated 
sputum samples, and 166 patients provided BAL specimens. Culture results and clinical 
diagnosis were used as gold standards. 
Results: The sensitivity and specificity of the DTB assay in detecting MTB in sputum specimens 
was significantly higher compared to AfB smear microscopy (83.7% and 82.4%, vs. 75.6%, and 
41.2%, respectively). The sensitivity and specificity of the DTB assay in detecting MTB in sputum 
samples was 77.2% and 100% compared to clinical diagnosis, while AfB smear had a sensitivity 
and specificity of 70.3% and 26.3%, respectively. Compared to culture, DTB had a sensitivity and 
specificity of 82.8% and 93.2%, respectively, in detecting MTB from BAL specimens; AfB smear 
had a sensitivity and specificity of 41.9% and 87.7%, respectively. Compared to clinical diagnosis, 
DTB had a sensitivity and specificity of 67.2% and 100%, respectively, in detecting MTB from BAL 
specimens; AfB smear had a sensitivity and specificity of 34.8% and 79.5%, respectively.
Conclusions: The superior performance of the DTB assay relative to AfB smear microscopy 
makes it a valuable tool to enable early diagnosis of MTB, thereby improving patient care 
and reducing transmission. 
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Introduction
Tuberculosis (TB), one of the most serious infectious diseases 
in the world, is responsible for approximately 2 million deaths 
every year.1 The incidence of TB has been reported to be almost 
75 per 100,000,2 and the rate of mortality is about six per 100,000 
in Taiwan.3 Almost 9% of the TB cases worldwide have been 
reported to occur simultaneously with human immunodeficiency 
virus (HIV), and one of the leading causes of death in HIV patients 
is due to opportunistic tuberculosis infection.4 Approximately 
8.8% of new patients with pulmonary tuberculosis in Taiwan 
have a delayed diagnosis,5 resulting in more extensive disease, 
more complications, and higher mortality. In addition, delayed 
treatment increases the risk of transmission.6 Therefore, 
rapid detection, accurate diagnostic methods, and appropriate 
treatment are essential to control successfully TB. 
The gold standard for diagnosing Mycobacterium tuberculosis 
(MTB) is culturing the bacilli from patient specimens.7 At 
present, the diagnosis of TB is most commonly made by direct 
acid-fast bacilli (AfB) smear examination and mycobacterial 
culture, which often takes three to six weeks. AfB smear 
microscopy, although rapid and inexpensive, has low 
sensitivity and specificity.8 In clinical laboratories in Taiwan, 
the typical sensitivity of AfB smear microscopy is 42.3%,9 
providing at best a preliminary diagnosis. Ziehl-Neelsen 
staining, auramine o rhodamine, and immunostaining 
using polyclonal anti-Mycobacterium bovis were all shown 
to be more efficient than bacteriology.10 Diagnostic yield 
of MTB in bronchoalveolar lavage (BAL) was far superior to 
other clinical specimens such as bronchial brushings, BAL 
fluid, transbronchial lung biopsy, and bronchial aspiration 
sputum, and although acquisition of these specimens is an 
invasive procedure, no complications or infectious events 
were reported.11 Bronchoscopy samples provided high rates 
of detection of MTB (87%) even in patients whose AfB smear 
samples were negative after testing with high-sensitivity 
methods, such aspolymerase chain reaction (PCR),12 and it 
was shown that 40% of these cases would have been found 
negative if bronchoscopy had not been performed. 
Becton Dickinson (Sparks, MD, USA) has developed and 
commercialized a semiautomated system, the BDProbeTec ET 
direct detection assay (DTB), for the rapid detection of MTB 
in respiratory specimens.13,14 The DTB assay, which does 
not use radioisotopes or require experienced operators, is a 
sensitive (82.7% to 95.8%) and specific (> 90%) diagnostic test 
for pulmonary TB in adults.9,13-18 The DTB assay has a slightly 
lower sensitivity in extrapulmonary samples.17,19 However, 
only two investigations have evaluated the DTB assay in the 
context of a standard clinical laboratory in Taiwan,18,20 and 
there is no comparison study on the effectiveness of the DTB 
assay and AfB smear microscopy in detecting MTB in patient 
specimens in Taiwan. 
The objective of this study was to evaluate the effectiveness 
of the DTB assay, compared to AfB smear microscopy, in 
detecting MTB in expectorated sputum samples or BAL 
specimens, using either culture or clinical diagnosis as the 
reference standard in a clinical setting characterized by high 
prevalence of TB. 
Materials and methods
Patients
The charts of 786 patients who presented at the Division 
of Infectious Diseases, at the Division of Chest, or at the 
Department of Internal Medicine of the Chung Shan Medical 
University Hospital (CSMUH) with symptoms of lung infection 
(pulmonary and extra-pulmonary symptoms) between August 
2006 and July 2009 were retrospectively reviewed. This study 
was approved by the Institutional Review Board of the CSMUH 
(No. CS05123). 
of the 786 patients, 151 patients were excluded because of 
loss to follow-up, referral to other hospitals, and missing data; 
53 patients were excluded because of extrapulmonary TB. of 
the 582 patients with pulmonary TB, 416 patients provided 
expectorated sputum samples, and 166 provided BAL samples, 
while 296 of the 416 patients were excluded due to lack of 
DTB data. Therefore, only 120 (416 – 296 = 120) patients who 
provided expectorated sputum samples and 166 patients 
who provide BAL samples were included in the final analysis. 
The DTB assay was directly compared with AfB smear 
microscopy and culture/clinical diagnosis in the 120 patients 
who provided expectorated sputum samples, and in the 166 
patients who provided BAL specimens. fig. 1 is a schematic 
representation of the study and shows the categorization of 
the patients into the different diagnostic groups.
Collection of sputum specimens
Patients suspected to have active pulmonary TB were 
instructed to collect spontaneous expectorated sputum 
samples at the hospital. Sputum samples were stored at 
20°C to 80°C for no longer than 48 hours before the assay. The 
sputum specimens were added to an equal volume of NaoH-
citrate-N-acetyl-L-cysteine for decontamination and digestion 
prior to culture and DTB assay. 
Collection of BAL specimens 
The indications for bronchoscopy to collect BAL specimens 
were: 1) when clinical symptoms and signs suggested TB, 
2) when sputum specimens could not be obtained, or 3) when 
a lung mass was present (to differentiate TB from malignancy). 
BAL specimens were collected as described by Kobashi et al.11 
during examination with a fiberoptic bronchoscope (model 
Bf20 or P20, olympus –Tokyo, Japan). The procedure was 
performed in a negative pressure room, and the clinicians 
used personal protective equipment during the examination. 
Patients undergoing this procedure signed an informed consent 
before bronchoscopy. 
Diagnostic testing 
Specimens for AfB smear microscopy were processed within 
24 hours after collection as previously described.18 Specimens 
that could not be processed upon receipt were stored at 2°C 
to 8°C for no longer than 48 hours. Culture was performed 
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with the BACTEC Mycobacteria Growth Indicator Tube 960 
system (Becton-Dickinson Diagnostic Instrument Systems – 
Sparks, MD, USA) as described previously.18 All liquid medium 
cultures were tested until they showed positive results, or for 
42 days.9,16,18 All specimens were inoculated onto conventional 
solid L-J medium. An individual plate was considered positive 
if colonies appeared on the surface. Identification of MTB 
was performed based on standard physical and biochemical 
characteristics, and was ultimately confirmed by AfB smear 
microscopy. 
BD ProbeTec ET (DTB system)
The DTB assay was performed according to the manufacturer’s 
instructions (Becton Dickinson) and as described previously.9,13-18 
Briefly, 500 μL of decontaminated specimen were added to 
1.0 mL of wash buffer, vortexed, and centrifuged. The pellet 
was heated in a self-contained oven to render the bacteria non-
viable. The pellet was then resuspended in lysis buffer, mixed, 
placed in a sonic water bath, centrifuged again, and the pellet 
was resuspended in sample neutralization buffer. The mixture was 
either vortexed, centrifuged, and tested, or frozen at -20°C. 
frozen specimens were thawed, heated, centrifuged, and then 
processed as described for fresh samples.
Samples and controls (150 μL; one positive and three 
negative controls per run) were dispensed into priming 
microwells, incubated at room temperature for at least 
20 minutes, and then heated at 72.5°C for 10 minutes. 
Samples (100 μL from each priming microwell) were then 
transferred into an amplification microwell of a preheated 
amplification microwell plate. The wells were sealed and 
the plate was immediately placed into the BDProbeTec ET 
instrument. After one hour, metric other than acceleration 
(MoTA, a measurement of the area under the relative 
fluorescent unit curve) values were noted for each sample 
and control. Samples with MoTA values greater than 3,400 
were considered positive for MTB complex deoxyribonucleic 
acid (DNA). If the MTB MoTA was < 3,400 and the internal 
amplification control MoTA was > 5000, then the sample result 
was considered negative. Samples with MTB MoTA values 
< 3,400 and internal amplification control values < 5,000 were 
considered to contain inhibitors of amplification. 
Clinical diagnosis of tuberculosis
Medical records were reviewed for evidence of TB based on 
the Taiwan guidelines for TB diagnosis and treatment21 and 
previous studies.7,22 All chest X-rays were read in a double-
blinded fashion by an infectious diseases specialist or a 
chest specialist, and by a radiologist. Briefly, five criteria for 
clinical diagnosis of TB were used: 1) patients with clinical 
symptoms and signs suggestive of TB diseases (such as 
sustained cough, weight loss, fever), chest X-rays that were 
typical of TB (typically showing a tuberculosis-like lesion), 
or a clinical response associated with administration of anti-
tuberculous drugs, in the absence of other antimicrobial 
agents (clinical response was defined as improvement of 
chest X-ray/clinical symptoms); 2) clinical samples from 
Fig. 1 - Flowchart for the categorization of patients into different diagnostic groups. TB, tuberculosis; BAL, bronchoalveolar 
lavage; DTB, direct detection assay. 
786 patients registry suspected TB
151 patients excluded
582 patients pulmonary TB
416 patients 
Expectorated sputum
116 patients 
BAL group
166 patients 
(acid-fast stain, culture, and 
DTB)
120 patients 
(acid-fast stain, culture, and 
DTB)
296 patients excluded 
(lack of DTB data)
53 patients extrapulmonary
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patients (including sputum, pleural fluid, gastric lavage fluid, 
BAL fluid or tissues) showing the presence of MTB in culture 
during the treatment period; 3) AfB smears or amplification 
of MTB complex by molecular methods of detection (PCR); 4) 
positive findings of TB on pathologic examination (caseating 
granulomas or AfB smear positive in the biopsy material); 
5) samples positive by PCR, as well as AfB smear positivity.
Culture-confirmed tuberculosis
Culture-confirmed TB was based on a positive culture of MTB 
from any specimen that originated from a patient who had 
another positive culture during the six months of clinical 
suspicion of TB. 
Statistical analyses
The sensitivity, specificity, positive predictive value (PPV), 
and negative predictive value (NPV) of DTB were calculated 
in comparison with AfB smear microscopy or TB culture 
results and, subsequently, in comparison with AfB smear or 
clinical diagnosis. Statistical analyses were performed using 
the Statistical Package for the Social Sciences 15.0 statistics 
software (SPSS Inc – Chicago, IL, USA).
Results
Patients’ disease status
This study analyzed data collected from 286 patients (120 
patients who provided expectorated sputum samples and 166 
patients who provided BAL samples). The final study sample 
comprised 198 males and 88 females, with a mean age of 
64.01 ± 18.66 years (range: 1 to 97 years), and 159 patients 
(55.6%) were over 65 years old. All 286 patients enrolled in this 
study were tested by DTB, AfB smear microscopy, and culture. 
All patients were diagnosed with pulmonary disease based on 
abnormal chest X-ray findings, such as infiltrations, fibrosis, 
miliary lesions, pleural effusions, cavitations, calcifications, 
mass lesions, and nodular lesions. of the 286 study patients 
with pulmonary disease, 62.6% (179/286) were positive by 
MTB culture and were considered to have a culture-confirmed 
diagnosis of TB, while 78.0% (223/286) of the patients fulfilled 
the criteria for a clinical diagnosis of TB (Table 1). 
Performance of the DTB assay and AFB smear microscopy vs. 
culture in expectorated sputum samples
The expectorated sputum samples provided by 120 patients 
were tested by the DTB assay, AfB smear microscopy, and 
culture. Eighty six of these patients were positive by the 
MTB culture test and were considered to have a culture-
confirmed TB, while 34 patients were negative by the MTB 
culture test (Table 2). A direct comparison of culture versus 
the use of AfB smear microscopy and the DTB assay in these 
patients was performed and showed that the DTB assay had 
a higher sensitivity than AfB smear microscopy (83.7% vs. 
75.6%). The DTB assay also had a higher specificity than 
AfB smear microscopy (82.4% vs. 41.2%). The positive and 
negative predictive values (PPV and NPV) were higher for the 
DTB assay compared to the AfB smear microscopy (Table 2). 
Performance of the DTB assay and AFB smear microscopy vs. 
clinical diagnosis in expectorated sputum samples
The clinical diagnosis was also used as the reference standard 
to compare the efficacy of AfB smear microscopy and the DTB 
assay in the 120 expectorated sputum samples (Table 2). The 
data showed that the DTB assay had a significantly higher 
sensitivity (77.2% vs. 70.3%) than AfB smear microscopy. The 
DTB assay also had a higher specificity (100% vs. 26.3%), and 
better NPV compared to AfB smear microscopy. Notably, the 
PPV of the DTB assay was 100% (Table 2). 
Sensitivity of the AFB smear microscopy and DTB assay vs. 
culture in BAL specimens
The results of AfB smear microscopy and DTB assay were 
further compared in 166 BAL samples, with either the culture 
or the clinical diagnosis as a gold standard. of the 166 patients 
who provided BAL samples, 93 patients were positive for MTB 
culture and were considered to have a culture-confirmed 
diagnosis of TB. The sensitivity and specificity of the DTB assay 
were demonstrated to be superior to those of the AfB smear 
microscopy. The positive and negative predictive values (PPV 
and NPV) were also higher for the DTB assay compared to AfB 
smear microscopy (Table 3).
Performance of the DTB assay and AFB smear microscopy vs. 
clinical diagnosis in BAL specimens
Clinical diagnosis was used as the gold standard to compare 
the efficacy of AfB smear microscopy and the DTB assay in the 
166 BAL samples (Table 3). A total of 122 patients fulfilled 
the criteria for clinical diagnosis. The DTB assay had a 
significantly higher sensitivity (67.2% vs. 34.8%) than AfB 
smear microscopy. The DTB assay also had a higher specificity 
(100% vs. 26.3%), and better NPV compared to AfB smear 
microscopy (Table 3). 
 n = 286
Age (years) 64.01 ± 18.66
Gender, n (%)
 Male 198 (69.2)
 female 88 (30.8)
Samples, n (%)
 Sputum specimens 120 (42.0)
 BAL 166 (58.0)
Number of positive patients, n (%)
 Clinical diagnosis 223 (78.0) 
BAL, bronchoalveolar lavage.
Table 1 - Patients’ demographics 
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            Culture
Sensitivity Specificity PPV NPV
 Positive Negative
AfB 
 Positive 65 20 75.6% 41.2% 76.5% 40.0%
 Negative 21 14
DTB 
 Positive 72 6 83.7%. 82.4% 92.3% 66.7%
 Negative 14 28
            Culture
Sensitivity Specificity PPV NPV
 Positive Negative
AfB 
 Positive 39 9 41.9% 87.7% 81.3% 54.2%
 Negative 54 64
DTB 
 Positive 77 5 82.8% 93.2% 93.9% 81.0%
 Negative 16 68
    Clinical diagnosis
Sensitivity Specificity PPV NPV
 Positive Negative
AfB 
 Positive 71 14 70.3% 26.3% 83.5% 14.3%
 Negative 30 5
DTB 
 Positive 78 0 77.2% 100% 100% 45.2%
 Negative 23 19
AfB, acid-fast bacilli; DTB, BDProbeTEC ET Mycobacterium tuberculosis complex direct detection assay; MTB, M. tuberculosis; PPV, positive 
predictive value; NPV, negative predictive value.
    Clinical diagnosis
Sensitivity Specificity PPV NPV
 Positive Negative
AfB 
 Positive 39 9 34.8% 79.5% 81.3% 29.7%
 Negative 83 35
DTB 
 Positive 82 0 67.2% 100% 100% 52.4%
 Negative 40 44
AfB, acid-fast bacilli; DTB, BDProbeTEC ET Mycobacterium tuberculosis complex direct detection assay; BAL, bronchoalveolar lavage; MTB,  
M. tuberculosis; PPV, positive predictive value; NPV, negative predictive value.
Table 2 - Detection of MTB in expectorated sputum samples (n = 120): comparison of AFB smear microscopy and DTB 
assay with culture or clinical diagnosis
Table 3 - Detection of MTB in BAL specimens (n = 166): comparison of AFB smear microscopy and DTB assay with 
culture method and clinical diagnosis
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Discussion
In this study, the effectiveness of the DTB assay in detecting 
MTB in expectorated sputum and in BAL specimens from 
patients with symptoms of a lung infection was evaluated. Since 
all the patients enrolled in this study had clinical symptoms 
and signs suggestive of TB, and patients were selected at the 
Division of Infectious Diseases, at the Division of Chest, 
the likelihood that the patients were truly infected with MTB was 
high. Not surprisingly, the percentage of respiratory specimens 
yielding positive TB culture results in the present study was 
62.6%, compared to a recent multi-center trial, which found that 
38.8% of the patients were smear and culture positive, while 
11.9% of the patients were smear negative and culture positive.23 
The high yield of MTB on culture in the present study could also 
be due to the use of both liquid and solid media, as stipulated 
by the Centers for Disease Control of Taiwan, which reduces 
the time required for culture from six to two weeks, and also 
increases the positive rate of bacterial culture. 
Since AfB smear microscopy had a sensitivity of only 
75.6% compared to culture, and of 70.3% compared to clinical 
diagnosis in detecting MTB from the sputum samples, the use 
of only AfB smear microscopy for diagnosis would result in 
fewer than half of the TB patients being promptly isolated 
and treated. The DTB assay exhibited higher sensitivity and 
specificity than AfB smear microscopy when compared to 
culture as the reference standard. The DTB assay also had a 
higher sensitivity and specificity than AfB smear microscopy 
when compared to clinical diagnosis. The DTB assay sensitivity 
data fall within the range of previously reported values (82.7% 
to 97.6%).12-14,16-18,24-31 Interestingly, six specimens were 
positive by the DTB assay but negative by culture. However, 
there were no DTB-positive specimens that were not also 
positive according to the criteria for clinical diagnosis, 
suggesting that the apparent false-positives seen on the DTB 
assay may actually represent false-negative culture results.
Treatment should be initiated to interrupt the transmission 
of MTB when the clinical presentation is highly suggestive of 
TB and the patient’s result from DTB assay is positive (even the 
smear result is negative). However, if the patient’s smear result 
is negative and clinical manifestations are uncertain, waiting 
until the culture results become available before beginning 
treatment is perhaps the better option.32 TB transmission 
from patients with negative smear results is relatively low 
(approximately 17%).33 A positive DTB result with a positive 
smear would indicate actual TB disease, and these patients 
should be isolated and receive antituberculous treatment until 
subsequent AfB smears are negative. However, a negative 
DTB result in a patient with an AfB-positive smear could 
indicate: 1) the presence of a NTM infection, and the patient 
could be released from isolation and avoid unnecessary anti-
tuberculous treatment;32,34 or 2) low specimen volume, low 
copy number of TB genes or due to the presence of unknown 
inhibitors in the sputum or BAL samples. 
In this study, BAL samples were collected: 1) based 
on clinical symptoms suggestive of TB, 2) when sputum 
samples could not be obtained,35-37 or 3) when a lung mass 
was observed (to differentiate TB from a malignancy).34 PCR-
restriction fragment length polymorphism has previously been 
used to detect mycobacterial species in bronchial washings, 
with a detection sensitivity > 80%.22,38 However, only a few 
studies have reported the detection of MTB in BAL fluid by the 
DTB assay.9,39 The present data suggest that the DTB assay 
offers an efficient alternative to AfB smear microscopy for the 
identification of MTB in BAL.
Although the cost of obtaining specimens by bronchoscopy 
and BAL is significantly higher than the costs associated with 
culture and identification (US$33 vs. US$13),24 the superior 
performance and the shorter time required for the DTB assay 
(one to seven days for the DTB assay versus 28 to 50 days for 
culture and identification) are important advantages. 
Among screening methods to detect pulmonary tuberculosis 
are AfB smear microscopy and culture on selective media in 
countries such as Nigeria,40 and the QuantifERoN TB test 
in countries such as Trinidad and Tobago and france.41,42 
Although the QuantifERoN test is more expensive than 
the tuberculin skin test, the rapidity and sensitivity of the 
assay makes it very useful in a field setting. The GenXpert 
MTB/RIf assay, which was recently endorsed by the World 
Health organization, rapidly detects the presence of MTB and 
can identify the mutations most frequently associated with 
rifampin resistance directly from smear-negative and smear-
positive clinical sputum samples in less than two hours.23,43 
The GenXpert MTB/RIf assay system is more sensitive than the 
DTB system, although both methods require approximately 
the same time (14 days; sometimes 42 days when the bacterial 
culture is negative). However, although the DTB system is more 
economical, it is only applicable for the detection of pulmonary 
bacteria or for tissues with positive AfB smears, and cannot 
be used for extra-pulmonary tissues or tissues with negative 
AfB smear results.
It is important to note that, even though all study patients 
included in this study had a high clinical suspicion of TB at 
enrollment, the significant difference in NPV and PPV between 
the DTB assay and AfB smear microscopy validates the use 
of the DTB assay in these patients. Limitations of this study 
are: 1) not all sputum and BAL samples which were subjected 
to TB microscopy, TB culture and DTB were provided to the 
authors for this study, due to the standard operating procedure 
followed by the hospital; 2) the retrospective nature of the 
study. However, the strength of this study lies in the large 
number of expectorated sputum samples tested (120) and the 
number of BAL specimens tested (166), compared to previous 
studies.36,35 
To summarize, it was demonstrated that early diagnosis 
using the DTB assay is a valuable tool for improving patient 
care and reducing transmission of TB, and for rapid diagnosis 
of MTB in the absence of sputum specimens. However, 
based on the present data, it is suggested that the DTB assay 
is insufficient as a single method for the diagnosis of TB; 
clinical diagnosis remains the ultimate guide in deciding the 
management of patients with TB. 
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